[Diagnostic opportunities of noninvasive brain thermomonitoring].

Development of new means and methods of cerebral temperature monitoring is an actual problem due to the fact that severity and outcomes of diseases in patients with brain damages (strokes, a head trauma) in big degree depend on development of neurogenetic fever and a local cerebral hyperthermia. The temperature monitoring, which is carried out by the implanted sensors, is applied in neurosurgical patients and is practically not used in patients with disorders of cerebral bloodflow. In this regard, noninvasive techniques of brain temperature registration are developing: proton nuclear magnetic resonance spectroscopy and registration of own electromagnetic radiation (EMR) at the high range of frequencies (microwave). The main objective of the study was to define of diagnostic opportunities of noninvasive temperature measurement of brain by means of microwave radiothermometry.

[First case of thrombolysis with non-immunogenic staphylokinase in a patient with ischemic stroke receiving dabigatran etexilate followed by thrombectomy]. / Pervyi sluchai tromboliticheskoi terapii pri pomoshchi neimmunnogennoi stafilokinazy u patsientki s ishemicheskim insul'tom, poluchayushchei dabigatrana eteksilat, s posleduyushchei trombektomiei.

Currently, five oral anticoagulants have been shown to be effective in preventing recurrent ischemic stroke and/or systemic embolism in patients with non-valvular atrial fibrillation. However, 1.1-2.2% of patients taking oral anticoagulants develop ischemic strokes. The use of oral anticoagulants limits the possibility of systemic thrombolytic therapy, as this is associated with an increased risk of symptomatic hemorrhagic transformation. The exception is cases when, with the help of a specific antagonist, it is possible to neutralize the effect of the anticoagulant in the shortest possible time and achieve normocoagulation. Currently, the Russian Federation allows two drugs for systemic thrombolytic therapy in patients with ischemic stroke in the «therapeutic window¼ up to 4.5 hours from the onset of the disease - recombinant tissue plasminogen activator and non-immunogenic staphylokinase, which showed no less efficacy and safety in the FRIDA study compared to recombinant tissue plasminogen activator. This article describes a clinical case of the first systemic thrombolytic therapy with a non-immunogenic staphylokinase after the use of idarucizumab in a patient taking dabigatran etexilate, followed by thrombectomy.